Join
Live feed
·
PRReleasevia Quantisnow
Gossamer Bio Inc. logo

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

ByQuantisnow·Wall Street's wire, on your screen.
GOSS· Gossamer Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GOSS (Gossamer Bio Inc.) and more on Quantisnow.